Literature DB >> 28257299

Optic pathway glioma of childhood.

Nailyn Rasool1, Jeffrey G Odel, Michael Kazim.   

Abstract

PURPOSE OF REVIEW: Optic pathway gliomas (OPG) are the most common tumor of the anterior visual pathway and can involve the optic nerve, chiasm, tract, and optic radiations. They are typically benign lesions, often pilocytic astrocytomas, which are diagnosed in childhood. We review the epidemiology, clinical presentation, diagnosis, and management of these lesions in patients with and without neurofibromatosis type 1 (NF-1). RECENT
FINDINGS: Most commonly, patients diagnosed with OPG have NF-1 especially if the lesions are bilateral. Such lesions tend to have a relatively indolent course and at least 50% of patients have no evidence of visual loss. Rarely, children without NF-1 may sporadically develop OPG with such lesions often having a more aggressive nature and greater propensity for visual dysfunction. The gold standard for diagnosis and follow-up are thorough neuro-ophthalmic examinations with specific attention to visual acuity. Management must be individualized and may comprise conservative follow-up, chemotherapy, radiation and/or surgical intervention.
SUMMARY: OPG may range in their behavior based upon the nature of the tumor (NF-1 or sporadic). Current guidelines recommend following patients with regular clinical examinations. Management of these lesions is highly individualized based upon the nature and extent of the lesion, visual function and side-effect profile of the treatment. Clinicians should be aware of the available options to determine which may be best suited for their patient.

Entities:  

Mesh:

Year:  2017        PMID: 28257299     DOI: 10.1097/ICU.0000000000000370

Source DB:  PubMed          Journal:  Curr Opin Ophthalmol        ISSN: 1040-8738            Impact factor:   3.761


  11 in total

1.  68Ga-NOTA-Aca-BBN(7-14) PET imaging of GRPR in children with optic pathway glioma.

Authors:  Jingjing Zhang; Yongji Tian; Deling Li; Gang Niu; Lixin Lang; Fang Li; Yuhan Liu; Zhaohui Zhu; Xiaoyuan Chen
Journal:  Eur J Nucl Med Mol Imaging       Date:  2019-07-03       Impact factor: 9.236

2.  Optic Nerve Gliomas.

Authors:  Edward J Wladis; Matthew A Adamo; Lauren Weintraub
Journal:  J Neurol Surg B Skull Base       Date:  2021-01-19

Review 3.  Neurosurgical experience of managing optic pathway gliomas.

Authors:  Ciaran Scott Hill; Mehdi Khan; Kim Phipps; Katherine Green; Darren Hargrave; Kristian Aquilina
Journal:  Childs Nerv Syst       Date:  2021-02-03       Impact factor: 1.475

4.  Verteporfin inhibits growth of human glioma in vitro without light activation.

Authors:  Ahmad Al-Moujahed; Katarzyna Brodowska; Tomasz P Stryjewski; Nikolaos E Efstathiou; Ioannis Vasilikos; Joanna Cichy; Joan W Miller; Evangelos Gragoudas; Demetrios G Vavvas
Journal:  Sci Rep       Date:  2017-08-08       Impact factor: 4.379

Review 5.  A systematic review of ongoing clinical trials in optic pathway gliomas.

Authors:  Ciaran Scott Hill; Sara Castro Devesa; William Ince; Anouk Borg; Kristian Aquilina
Journal:  Childs Nerv Syst       Date:  2020-06-18       Impact factor: 1.475

6.  [Imaging of orbital tumors in children].

Authors:  Dounia Basraoui; Fadwa Jaafari; Hicham Jalal
Journal:  Pan Afr Med J       Date:  2018-04-02

7.  Epidemiology and Survival of Patients With Optic Pathway Gliomas: A Population-Based Analysis.

Authors:  Huanbing Liu; Yong Chen; Xiaowei Qin; Zheng Jin; Yining Jiang; Yubo Wang
Journal:  Front Oncol       Date:  2022-02-11       Impact factor: 6.244

Review 8.  Recent Update in Pharmacological Agents for Optic Pathway Glioma.

Authors:  Meerim Park
Journal:  Brain Tumor Res Treat       Date:  2022-04

Review 9.  Pediatric Glioma at the Optic Pathway and Thalamus.

Authors:  Eun Suk Park; Jun Bum Park; Young-Shin Ra
Journal:  J Korean Neurosurg Soc       Date:  2018-05-01

Review 10.  Theragnostic Aspects and Radioimmunotherapy in Pediatric Tumors.

Authors:  Andrea Cimini; Maria Ricci; Agostino Chiaravalloti; Luca Filippi; Orazio Schillaci
Journal:  Int J Mol Sci       Date:  2020-05-28       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.